Carbetocin Versus Syntometrine for the Third Stage of Labour

Status Completed

Clinical Trial Summary

Intramuscular carbetocin is as effective as intramuscular syntometrine for the prevention of postpartum haemorrhage

Clinical Trial Description

Postpartum haemorrhage(PPH)or excessive bleeding at or after childbirth is a potentially life threatening complication and is one of the major contributors to maternal mortality and morbidity worldwide (Lewis 2001).Among the various agents that have been studied in addition to the routine oxytocin and syntometrine (which has adverse effects),oxytocin agonist (carbetocin) appears to be the most promising for this indication(Chong 2004).

Carbetocin is a licensed medication for the use of prevention of postpartum haemorrhage in Singapore and many other countries. It is a long-acting synthetic octapeptide analogue of oxytocin with agonist properties.The clinical and pharmacological properties of carbetocin are similar to those of naturally occurring oxytocin. Like oxytocin, carbetocin binds to oxytocin receptors present on the smooth musculature of the uterus, resulting in rhythmic contractions of the uterus, increased frequency of existing contractions, and increased uterine tone. In pharmacokinetic studies, intravenous injections of carbetocin produced tetanic uterine contractions within two minutes, lasting six minutes, followed by rhythmic contractions for a further hour.Intramuscular injection produced tetanic contractions in less than two minutes, lasting about 11 minutes, and followed by rhythmic contractions for an additional two hours. The prolonged duration of activity after intramuscular compared with the intravenous carbetocin was significant(Hunter 1992). In comparison to oxytocin, carbetocin induces a prolonged uterine response when administered postpartum, in terms of both amplitude and frequency of contractions.

The potential advantage of intramuscular carbetocin over intramuscular oxytocin is its longer duration of action. Its relative lack of gastrointestinal and cardiovascular side-effects should also prove advantageous compared to syntometrine and other ergot alkaloids. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00499005
Study type	Interventional
Source	National University Hospital, Singapore
Contact
Status	Completed
Phase	Phase 4
Start date	November 2006
Completion date	July 2009

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02509351` - Could Pre-operative Rectal Misoprostol Reduce Intra-operative Blood Loss During Ceserean Section?	Phase 2/Phase 3
Completed	`NCT01931423` - The Influence of Placental Drainage of Management of the Third Stage of Labor:a Randomized Controlled Study	N/A
Completed	`NCT01485562` - Treatment of Postpartum Haemorrhage (PPH) Using Misoprostol in Home Births	N/A
Completed	`NCT01359878` - Fibrinogen Concentrate as Initial Treatment for Postpartum Haemorrhage: A Randomised Clinically Controlled Trial	Phase 2/Phase 3
Completed	`NCT00872469` - World Maternal Antifibrinolytic Trial	Phase 3
Completed	`NCT02704780` - Two Different Regimens of Misoprostol in Retained Placenta	Phase 2
Not yet recruiting	`NCT02396303` - Carbetocin Versus Oxytocin in Caesarean Section for the Control of Postpartum Haemorrhage	Phase 0
Completed	`NCT01895218` - Treatment of Women After Postpartum Haemorrhage	Phase 3
Completed	`NCT01931410` - The Effect of Rectal and Sublingual Misoprostol Administration in Postpartum or Intrapartum Haemorrhage at Elective Caesarean Delivery: a Randomized Controlled Trial	Phase 4
Recruiting	`NCT02187874` - Timing of Umbilical Cord Occlusion in Premature Babies( <33 w). Delayed vs Early.	N/A
Withdrawn	`NCT01910675` - PCC and Fibrinogen Compared With FFP in PPH	Phase 4
Completed	`NCT02562300` - Uterotonics Using to Reduce Bleeding at Cesarean Section	Phase 2
Completed	`NCT01044082` - Prevention of Post-partum Haemorrhage	N/A
Completed	`NCT01116050` - Intrarectal Misoprostol in Postpartum Haemorrhage	Phase 3
Completed	`NCT02149472` - Towards Better Prognostic and Diagnostic Strategies for Haemostatic Changes During Major Obstetric Haemorrhage
Recruiting	`NCT02492087` - Topical Tranexamic Acid in Caesarean Section	Phase 3
Completed	`NCT02468310` - Evaluating the Effects of SMS Text Messaging Support System Among Frontline Health Workers in Ghana	N/A
Recruiting	`NCT02136719` - Bimanual Uterine Compression to Reduce Blood Loss and Prevent Postpartum Haemorrhage After Vaginal Delivery	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.